Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB).
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4658546
Author(s) Stoffel, Sandro T; Colaninno, Angelo; Bräm, René; Schwenkglenks, Matthias
Author(s) at UniBasel Schwenkglenks, Matthias
Stoffel, Sandro
Year 2022
Title Pneumococcal vaccination among adult risk patient with axial spondyloarthritis in Switzerland: Data from the survey of the ankylosing spondylitis association of Switzerland (SVMB).
Journal Vaccine
Volume 40
Number 43
Pages / Article-Number 6206-6210
Keywords Adults; AxSpA; Coverage; Pneumococcal vaccine; Survey
Mesh terms Adult; Axial Spondyloarthritis; Female; Humans; Spondylitis, Ankylosing, drug therapy; Switzerland, epidemiology; Vaccination; Vaccines, therapeutic use
Abstract

While in Switzerland, pneumococcal vaccination is recommended for adult patients with axial spondyloarthritis (axSpA) treated with biological drugs, since 2014, little is known about the vaccination status of this specific patient population. This study assessed their vaccination status as part of a larger online survey by the ankylosing spondylitis association of Switzerland (SVMB). Out of 1560 who participated in the survey, 834 (53.5%) were eligible for the analysis. Vaccine coverage was low at 32.5% (271/834). Women and patients who got a flu shot every year were more likely to be covered. Age was negatively associated with being vaccinated. Most (54.2%; 147/271) were vaccinated by their general practitioner. Almost two-thirds of those who had not received the vaccine stated that it had not been offered to them (64.1%; 302/471). In summary, the vaccination coverage is low, but might be increased if the vaccine was offered systematically by general practitioners and specialists.

ISSN/ISBN 1873-2518
Full Text on edoc
Digital Object Identifier DOI 10.1016/j.vaccine.2022.09.056
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/36175212
   

MCSS v5.8 PRO. 0.326 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
12/05/2024